Patents Examined by Howard E. Schain
  • Patent number: 5569648
    Abstract: The invention features a method of using insulin-like growth factor-I (IGF-I) or insulin-like growth factor-III (IGF-III) to prevent or treat peripheral neuropathy in a mammal.
    Type: Grant
    Filed: December 29, 1994
    Date of Patent: October 29, 1996
    Assignees: Cephalon, Inc., Albert Einstein College of Medicine of Yeshiva University
    Inventors: Michael E. Lewis, Stuart C. Apfel, John A. Kessler
  • Patent number: 5569647
    Abstract: The invention relates to a compound selected from those of formula (I) (SEQ ID NO:1): ##STR1## in which R.sub.1, R.sub.2, X.sub.1 and X.sub.2 are as defined in the description, useful as inhibitor of the proliferation component of vascular smooth muscle cells.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 29, 1996
    Assignee: Adir et Compagnie
    Inventors: Jean-Luc Fauchere, Christophe Thurieau, Jean-Paul Vilaine, Philip Janiak
  • Patent number: 5567676
    Abstract: The present invention concerns new antiobiotic substances demoninated de-acyl antibiotics A40926, de-acyl antibiotic A 40926P and antibiotic A 40926 amino glucronyl aglycon, and the use of these substances in the treatment of infectious diseases involving microorganisms susceptible to it.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: October 22, 1996
    Assignee: Gruppo Lepetit S.p.A
    Inventors: Enrico Selva, Grazia Beretta, Angelo Borghi, Maurizio Denaro
  • Patent number: 5567679
    Abstract: The present invention relates to the use of Calcitonin Gene Related Peptide (CGRP), either topically or intramuscularly, as a treatment for hair loss. The use of calcitonin or CGRP, either topically or intramuscularly, for hair loss includes the steps of preparing a liquid carrier, adding calcitonin to the carrier, injecting the mixture into a subject intramuscularly, intravascularly, intradermally or subcutaneously, and analyzing results on the subject.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: October 22, 1996
    Inventor: Theodore J. Daly
  • Patent number: 5565428
    Abstract: A method is disclosed that comprises administering insulin-like growth factor-I (IGF-I) to a mammal so as to sustain its biological activity in the mammal comprising administering a therapeutically effective amount of IGF-I to the mammal to provide an exposure to IGF-I for a period of time that stimulates the maximum biological response in the mammal, then discontinuing said administration for a period of time equal to or less than the time period used for administration, and repeating this pattern of administration and discontinuance of administration for a period as long as necessary to achieve or maintain the desired biological response in the mammal.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: October 15, 1996
    Assignees: Genentech, Inc., Washington University
    Inventors: Ross G. Clark, Neil Gesundheit, Marc R. Hammerman, Steven B. Miller
  • Patent number: 5565423
    Abstract: Cyclopeptides and their use as absorption promoters when applied to the mucosaThe invention relates to a compound of the formula I ##STR1## or a physiologically tolerated salt thereof, in which X is a basic L- or D-amino acid,Y is a neutral or basic L- or D-amino acid,Z is a neutral or basic L- or D-amino acid, which can be identical to or different from Y,R.sup.1 is an N-bonded acyl radical of the formula II ##STR2## in which Ar is a phenyl radical, which is optionally substituted by 1, 2 or 3 identical or different radicals from the series comprising hydroxyl, (C.sub.1 -C.sub.4)-alkoxy, amino, carboxyl, (C.sub.1 -C.sub.4)-alkylamino and halogen, or is a 2-aminothiazol-4-yl radical,p is an integer from zero to 4 and q, n, m and 1 independently of one another are zero or 1.
    Type: Grant
    Filed: April 7, 1995
    Date of Patent: October 15, 1996
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Jurgen Sandow, Walter Durckheimer, Gunter Ditzinger, Hans-Peter Merkle
  • Patent number: 5561112
    Abstract: Pseudopeptides of formula I in free or salt form ##STR1## wherein A, B, R.sub.1, X, Y and m are defined as in claim 1, and their use in the prophylactic and acute treatment of thrombosis.
    Type: Grant
    Filed: March 1, 1994
    Date of Patent: October 1, 1996
    Assignee: Sandoz Ltd.
    Inventors: Georg Kottirsch, Rainer Metternich
  • Patent number: 5559095
    Abstract: A method and compositions for reducing neuronal damage related to an ischemic condition in a mammalian subject are described. The method includes administration of a voltage-gated calcium channel-blocking compound to the subject, 4-24 hours after the onset of the ischemic condition. Such a calcium channel blocking compound is effective to block norepinephrine release in mammalian CNS neuronal cells and is characterized by specific, high affinity binding to omega-conotoxin MVIIA binding sites. Also disclosed are novel peptide structures useful in the treatment method of the invention.
    Type: Grant
    Filed: November 12, 1991
    Date of Patent: September 24, 1996
    Assignee: Neurex Corporation
    Inventors: George P. Miljanich, Stephen S. Bowersox, James A. Fox, Karen L. Valentino, Robert S. Bitner, Donald H. Yamashiro
  • Patent number: 5547938
    Abstract: Therapeutic agents for the digestive tract diseases which comprise glicentin as active ingredients.
    Type: Grant
    Filed: January 25, 1995
    Date of Patent: August 20, 1996
    Assignee: Nisshin Flour Milling Co., Ltd.
    Inventors: Seiki Matsuno, Iwao Sasaki, Akira Ohneda, Kazuyuki Sasaki, Yohei Natori, Tomohisa Nagasaki
  • Patent number: 5548062
    Abstract: The present invention is a peptide having from 5 to 20 amino acid residues having tumor cell invasion-inhibiting activities. As such a peptide, a peptide represented by any one of the formulas (1) to (13) is preferred among peptides.Further, the present invention is a cancer metastasis inhibitor comprising the above peptide as an active ingredient.Furthermore, the present invention is a peptide complex having a peptide having tumor cell invasion-inhibiting activities and a polymer derived from a vital body chemically bonded to each other. As such a peptide, a peptide represented by any one of the formulas (1) to (14) is preferred among peptides. As the polymer derived from a vital body, a protein such as albumin or globulin is preferred.Still further, the present invention is a cancer metastasis inhibitor comprising the above peptide complex as an active ingredient.
    Type: Grant
    Filed: November 26, 1993
    Date of Patent: August 20, 1996
    Assignee: Asahi Glass Company Ltd.
    Inventors: Atsushi Isoai, Yuko Hama, Hiromichi Kumagai
  • Patent number: 5547930
    Abstract: The present invention relates to insulin crystals comprising ASP.sup.B28 and protamine, and pharmaceutical preparations containing same. The crystals and preparations exhibit rapid onset and prolonged activity when administered in vivo.
    Type: Grant
    Filed: September 28, 1993
    Date of Patent: August 20, 1996
    Assignee: Novo Nordisk A/S
    Inventor: Per Balschmidt
  • Patent number: 5543392
    Abstract: The present invention provides an activating agent of digestive tract cells, which contains an epidermal growth factor, lactoferrins, a hydrolysate of the lactoferrins, or a mixture thereof.The activating agent of digestive tract cells of the present invention has such effects as prevention and improvement of a damage to the digestive tract, improvement of digestive tract functions deteriorating with age, and acceleration of growth and proliferation of digestive tract cells of a newborn. It is also possible to add it to, or mixed with, various food products to obtain digestive tract cels activating foods.
    Type: Grant
    Filed: April 3, 1995
    Date of Patent: August 6, 1996
    Assignee: Morinaga Milk Industry Co., Ltd.
    Inventors: Mamoru Tomita, Seiichi Shimamura, Yasuo Fukuwatari, Ichizo Shinoda
  • Patent number: 5541159
    Abstract: Peptide derivatives selected from (i) a calcitonin peptide and a LHRH antagonist peptide modified by at least one sugar residue and/or at least one short polyhydroxy compound or derivative, and (ii) a calcitonin peptide modified by at least one formyl and/or at least C.sub.3-5 alkyl attached to an amino group other than a N-terminal amino group, and (iii) a calcitonin peptide modified by a combination of said substituents, with the provisos thati) when the calcitonin peptide comprises at least one sugar residue a), this sugar residue is attached by a coupling other than a direct N-glycosidic bond to an .omega.-amino group of an .omega.-amino substituted side chain in the 24 position, andii) when the LHRH antagonist comprises at least one sugar residue a), this sugar residue is an Amadori sugar residue attached by a coupling other than a direct N-glycosidic bond to an .omega.-amino group of an .omega.
    Type: Grant
    Filed: November 29, 1994
    Date of Patent: July 30, 1996
    Assignee: Sandoz Ltd.
    Inventors: Rainer Albert, Wilfried Bauer, Fran.cedilla.ois Cardinaux, Janos Pless
  • Patent number: 5541286
    Abstract: Pseudopeptide compounds based on a modified bradykinin sequence are potent bradykinin receptor antagonists. Amino acids at at positions 2 through 5 are replaced by olefinic aminoalkenoyl groups to reduce the peptide nature of the compounds.The analogs produced are useful in treating conditions and diseases of a mammal and human in which an excess of bradykinin or related kinins are produced or injected such as by insect bites.
    Type: Grant
    Filed: July 28, 1994
    Date of Patent: July 30, 1996
    Assignee: Scios Nova Inc.
    Inventor: Donald J. Kyle
  • Patent number: 5533836
    Abstract: Methods and compositions for stimulating the growth of osteoblasts are disclosed. A composition comprising platelet derived growth factor and vitamin D is applied to osteoblasts in an amount sufficient to stimulate their growth. The methods may be used to promote the growth of osteoblasts in vitro or to promote the healing of bone defects in vivo.
    Type: Grant
    Filed: March 22, 1995
    Date of Patent: July 9, 1996
    Assignee: ZymoGenetics, Inc.
    Inventor: Emma E. Moore
  • Patent number: 5532215
    Abstract: The present invention provides a method for inhibiting viral proliferation by preventing or inhibiting viral replication or killing the viruses on contact. Viral replication is prevented or inhibited through the use of serine protease inhibitors, their analogs, salts, conjugates or derivatives.
    Type: Grant
    Filed: October 3, 1994
    Date of Patent: July 2, 1996
    Inventors: John Lezdey, Allan Wachter
  • Patent number: 5527776
    Abstract: This invention includes a method of treating subjects with immunologic and hematologic disorders, such as immune deficiencies and anemias characterized by deficient total hemoglobin. The treatment includes administering to the subject insulin-like growth factor binding protein-3 (IGFBP-3), alone or in a complex including an insulin-like growth factor (IGF), in an amount sufficient to improve the immunologic and/or hematologic disorder, for example, increasing the level of total hemoglobin or improving immune deficiencies, such as occur post-chemotherapy. Another aspect of the invention includes administering IGFBP-3 alone to treat IGF-driven lymphoproliferative conditions, such as leukemias, inflammatory skin diseases, and nasal polyps.
    Type: Grant
    Filed: February 23, 1995
    Date of Patent: June 18, 1996
    Assignee: Celtrix Pharmaceuticals
    Inventors: Joseph A. Carlino, Howard R. Higley, Christopher A. Maack
  • Patent number: 5527773
    Abstract: Synthetic peptides corresponding to different regions of the human keratin 1 chain can disassemble preformed keratin intermediate filaments or inhibit filament assembly both in vitro and in vivo. The disruption of keratin filaments may have therapeutic applications in the treatment of epithelial abnormalities.
    Type: Grant
    Filed: August 25, 1993
    Date of Patent: June 18, 1996
    Assignee: United States of America
    Inventors: Peter M. Steinert, Robert D. Goldman, John J. DiGiovanna
  • Patent number: 5527771
    Abstract: Methods for treatment of diabetes and other insulin-requiring conditions by administering insulin and a calcitonin with or without amylin, and methods for treatment of hypoglycemic conditions by administering a calcitonin alone or in combination with glucagon and/or an amylin, and related compositions.
    Type: Grant
    Filed: June 14, 1994
    Date of Patent: June 18, 1996
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Kevin Beaumont, Andrew A. Young
  • Patent number: RE35277
    Abstract: Compositions for the prevention of, and for the treatment of autoimmune diseases which comprise as active ingredient membrane material shed from autoimmune T lymphocytes, or T lymphocytes activated by a pressure application and release process. There is also provided a process for obtaining such active materials and for preparing pharmaceutical compositions for these.
    Type: Grant
    Filed: September 6, 1988
    Date of Patent: June 18, 1996
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Irun R. Cohen, Meir Shinitzky